Bioethics Blogs

Stop Price Gouging Sick People

by Craig Klugman, Ph.D.

More and more frequently, stories are appearing of drug companies buying patents of investment firms buying drug companies and then raising the cost dramatically. First there was Turing Pharmaceuticals that raised the cost of a toxoplasmosis drug by 5500% after the company bought the patent. EpiPen is currently in the news with its leaders having to appear before Congress and explain why it’s price increased 791% after being acquired by Mylan Pharmaceuticals. Now Novum Pharma, after purchasing several drugs from Primus Pharmaceuticals has raised the price of drugs used to treat eczema and skin infections.…

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.